Letter to the editor: Fair comparisons in the arena of risk scores by Wang, J, Geskus, R, Leeflang, M, Ponsioen, C

A novel prognostic model for transplant-free survival in primary sclerosing cholangitis by de Vries, E, Wang, J, Williamson, K, Leeflang, M, Boonstra, K, Weersma, R, Beuers, U, Chapman, R, Geskus, R, Ponsioen, C

Biosimilars in IBD: hope or expectation? by Gecse, K, Khanna, R, van den Brink, G, Ponsioen, C, Löwenberg, M, Jairath, V, Travis, S, Sandborn, W, Feagan, BG, D'Haens, G

Serum Immunoglobulin G4 and Immunoglobulin G1 for Distinguishing Immunoglobulin G4-Associated Cholangitis From Primary Sclerosing Cholangitis by Boonstra, K, Culver, E, Wenniger, L, van Heerde, M, van Erpecum, K, Poen, A, van Nieuwkerk, K, Spanier, B, Witteman, B, Tuynman, H, van Geloven, N, van Buuren, H, Chapman, R, Barnes, E, Beuers, U, Ponsioen, C

Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. by Boonstra, K, Culver, E, de Buy Wenniger, L, van Heerde, M, van Erpecum, K, Poen, A, van Nieuwkerk, K, Spanier, B, Witteman, B, Tuynman, H, van Geloven, N, van Buuren, H, Chapman, R, Barnes, E, Beuers, U, Ponsioen, C

International experience of vedolizumab in primary sclerosing cholangitis and inflammatory bowel disease by Williamson, K, Lytvyak, E, De Krijger, M, Trivedi, P, Estes, D, Yu, L, Pratt, D, De Vries, A, Daretti, L, Liu, C, Bowlus, C, Marschall, H, Montano-Loza, A, Chapman, R, Van Der Woude, C, Marzioni, M, Keshav, S, Ponsioen, C, Hirschfield, G, Levy, C

Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. by de Vries, E, de Krijger, M, Färkkilä, M, Arola, J, Schirmacher, P, Gotthardt, D, Goeppert, B, Trivedi, P, Hirschfield, G, Ytting, H, Vainer, B, Buuren, H, Biermann, K, Harms, M, Chazouilleres, O, Wendum, D, Kemgang, A, Chapman, R, Wang, L, Williamson, K, Gouw, A, Paradis, V, Sempoux, C, Beuers, U, Hübscher, S, Verheij, J, Ponsioen, C

Differential association of two <it>PTPN22</it> coding variants with Crohn’s disease and ulcerative colitis by Weersma R K, Roberts R L, Gearry R B, Ponsioen C Y, Wijmenga C, van Bodegraven A A, Crusius J B, Barclay M L, Bottini N, López-Nevot M A, Cueto I, Nieto A, Alcain G, Taxonera C, Mendoza J L, Rodrigo L, Cardeña C, van Sommeren S, Gómez-García M, Fransen K, Espino-Paisán L, Diaz-Gallo L M, Urcelay E, Merriman T R, Alizadeh B Z, Martin J

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases by Lynch, K, Chapman, R, Keshav, S, Montano-Loza, A, Mason, A, Kremer, A, Vetter, M, De Krijger, M, Ponsioen, C, Trivedi, P, Hirschfield, G, Schramm, C, Liu, C, Bowlus, C, Estes, D, Pratt, D, Hedin, C, Bergquist, A, De Vries, A, Janneke Van Der Woude, C, Yu, L, Assis, D, Boyer, J, Ytting, H, Hallibasic, E, Trauner, M, Marschall, H, Daretti, L, Marzioni, M, Yimam, K, Perin, N, Floreani, A, Beretta-Piccoli, B, Rogers, J, International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy, C